Miloš Greguš

406 total citations
10 papers, 227 citations indexed

About

Miloš Greguš is a scholar working on Epidemiology, Genetics and Surgery. According to data from OpenAlex, Miloš Greguš has authored 10 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Epidemiology, 8 papers in Genetics and 4 papers in Surgery. Recurrent topics in Miloš Greguš's work include Microscopic Colitis (8 papers), Inflammatory Bowel Disease (8 papers) and Helicobacter pylori-related gastroenterology studies (4 papers). Miloš Greguš is often cited by papers focused on Microscopic Colitis (8 papers), Inflammatory Bowel Disease (8 papers) and Helicobacter pylori-related gastroenterology studies (4 papers). Miloš Greguš collaborates with scholars based in United States, Czechia and Italy. Miloš Greguš's co-authors include William J. Sandborn, Dino Tarabar, Silvio Danese, Miles Sparrow, Kenneth J. Gorelick, Joo Sung Kim, Maria Kłopocka, Séverine Vermeire, Fabio Cataldi and Tomáš Vaňásek and has published in prestigious journals such as The Lancet, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Miloš Greguš

10 papers receiving 224 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Miloš Greguš United States 5 189 118 78 37 35 10 227
Dulce Soler-Ferran United States 2 149 0.8× 157 1.3× 75 1.0× 30 0.8× 17 0.5× 3 259
Swati Tole United States 6 121 0.6× 86 0.7× 62 0.8× 30 0.8× 20 0.6× 11 183
Martina Goetsch United States 7 218 1.2× 61 0.5× 125 1.6× 65 1.8× 32 0.9× 40 296
Carrie Derkowski United States 6 130 0.7× 130 1.1× 47 0.6× 47 1.3× 12 0.3× 8 248
Arzu Meltem Demir Türkiye 8 76 0.4× 152 1.3× 29 0.4× 37 1.0× 15 0.4× 19 234
Nathalie Clerget–Chossat France 5 99 0.5× 259 2.2× 45 0.6× 38 1.0× 15 0.4× 5 358
Jahnavi Aluri India 10 58 0.3× 198 1.7× 44 0.6× 9 0.2× 22 0.6× 15 267
Bella Shadur Australia 10 49 0.3× 97 0.8× 35 0.4× 15 0.4× 57 1.6× 20 214
Joris van Montfrans Netherlands 10 75 0.4× 203 1.7× 36 0.5× 11 0.3× 30 0.9× 13 291
Saad Pathan United Kingdom 6 174 0.9× 133 1.1× 93 1.2× 60 1.6× 30 0.9× 6 252

Countries citing papers authored by Miloš Greguš

Since Specialization
Citations

This map shows the geographic impact of Miloš Greguš's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miloš Greguš with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miloš Greguš more than expected).

Fields of papers citing papers by Miloš Greguš

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miloš Greguš. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miloš Greguš. The network helps show where Miloš Greguš may publish in the future.

Co-authorship network of co-authors of Miloš Greguš

This figure shows the co-authorship network connecting the top 25 collaborators of Miloš Greguš. A scholar is included among the top collaborators of Miloš Greguš based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miloš Greguš. Miloš Greguš is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Reinisch, Walter, William J. Sandborn, Silvio Danese, et al.. (2021). Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. Journal of Crohn s and Colitis. 15(6). 938–949. 25 indexed citations
2.
Danese, Silvio, William J. Sandborn, Walter Reinisch, et al.. (2019). 772 Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT II. The American Journal of Gastroenterology. 114(1). S448–S449. 1 indexed citations
3.
Reinisch, Walter, William J. Sandborn, Silvio Danese, et al.. (2019). Tu1737 – Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Ulcerative Colitis: Results from the Open-Label Extension Study Turandot Ii. Gastroenterology. 156(6). S–1105. 1 indexed citations
4.
Reinisch, Walter, William J. Sandborn, Silvio Danese, et al.. (2019). P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II). Gastroenterology. 156(3). S25–S26. 1 indexed citations
5.
Reinisch, Walter, William J. Sandborn, Silvio Danese, et al.. (2019). P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II). Inflammatory Bowel Diseases. 25(Supplement_1). S18–S18. 4 indexed citations
6.
7.
Vermeire, Séverine, William J. Sandborn, Silvio Danese, et al.. (2017). Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. 390(10090). 135–144. 146 indexed citations
8.
9.
10.
Sands, Bruce E., William J. Sandborn, Tom Creed, et al.. (2012). Basiliximab Does Not Increase Efficacy of Corticosteroids in Patients With Steroid-Refractory Ulcerative Colitis. Gastroenterology. 143(2). 356–364.e1. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dulce Soler-Ferran Breakdown of academic impact, for papers by Swati Tole Breakdown of academic impact, for papers by Martina Goetsch Breakdown of academic impact, for papers by Carrie Derkowski Breakdown of academic impact, for papers by Arzu Meltem Demir Breakdown of academic impact, for papers by Nathalie Clerget–Chossat Breakdown of academic impact, for papers by Jahnavi Aluri Breakdown of academic impact, for papers by Bella Shadur Breakdown of academic impact, for papers by Joris van Montfrans Breakdown of academic impact, for papers by Saad Pathan
Rankless by CCL
2026